A detailed history of Rhumbline Advisers transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 42,714 shares of LBPH stock, worth $2.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,714
Previous 42,476 0.56%
Holding current value
$2.56 Million
Previous $1.15 Million 23.95%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$27.58 - $39.5 $6,564 - $9,401
238 Added 0.56%
42,714 $1.42 Million
Q2 2024

Aug 01, 2024

BUY
$17.0 - $27.03 $212,500 - $337,875
12,500 Added 41.7%
42,476 $1.15 Million
Q1 2024

May 09, 2024

BUY
$18.89 - $26.06 $260,493 - $359,367
13,790 Added 85.2%
29,976 $647,000
Q3 2023

Nov 09, 2023

BUY
$5.49 - $7.49 $4,413 - $6,021
804 Added 5.23%
16,186 $89,000
Q2 2023

Aug 08, 2023

BUY
$4.19 - $10.05 $64,450 - $154,589
15,382 New
15,382 $112,000

Others Institutions Holding LBPH

About Longboard Pharmaceuticals, Inc.


  • Ticker LBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,586,000
  • Market Cap $815M
  • Description
  • Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...
More about LBPH
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.